This inventor holds 1 USPTO granted patent. Top assignee: Ribozyme Pharmaceuticals, Incorporated. Active years: 1998.
Company Filing History:
Years Active: 1998
Title: Kevin Kisich: Innovator in Enzymatic RNA Technology
Introduction
Kevin Kisich is a notable inventor based in Lafayette, Colorado. He has made significant contributions to the field of enzymatic RNA molecules, particularly through his innovative work on TNF-.alpha. ribozymes. His research focuses on the development of RNA molecules that cleave TNF-.alpha. mRNA, which has important implications for therapeutic applications.
Latest Patents
Kevin Kisich holds a patent for TNF-.alpha. ribozymes, which are enzymatic RNA molecules designed to target and cleave TNF-.alpha. mRNA. This patent represents a significant advancement in the understanding and manipulation of RNA for potential medical treatments.
Career Highlights
Kisich is associated with Ribozyme Pharmaceuticals, Incorporated, where he has been instrumental in advancing research in RNA technology. His work has contributed to the development of novel therapeutic strategies that leverage the unique properties of ribozymes.
Collaborations
Throughout his career, Kevin has collaborated with esteemed colleagues, including Sean M. Sullivan and Kenneth G. Draper. These collaborations have fostered a productive research environment that has led to innovative discoveries in the field of enzymatic RNA.
Conclusion
Kevin Kisich's contributions to enzymatic RNA technology highlight his role as a leading inventor in this specialized field. His work continues to pave the way for advancements in therapeutic applications, showcasing the importance of innovation in science.